Arovella Therapeutics (ALA) H2 2025 earnings summary

Executive summary

• Revenue increased 700% year-over-year to $136,000, while net loss after tax decreased 14.1% to $7,509,166 compared to the prior year.

• Net tangible assets per share rose to 1.69 cents from 1.07 cents year-over-year.

• Cash reserves grew to $20.9 million, supporting ongoing clinical and R&D activities.

• A $15 million share placement was completed, strengthening the balance sheet and funding clinical milestones.

Financial highlights

• Revenue: $136,000 (2024: $17,000), driven by increased R&D tax incentive income.

• Net loss: $7,509,166 (2024: $8,746,035), reflecting reduced expenses and higher income.

• Net assets: $20,076,003 (2024: $11,228,047); cash and cash equivalents: $20,877,185 (2024: $12,714,407).

• No dividends declared or paid for the year.

Outlook and guidance

• Well-funded to complete enrolment in the phase 1 trial for lead product ALA-101 targeting CD19-positive blood cancers.

• Focus on advancing ALA-101 to first-in-human clinical trials and expanding the iNKT cell platform to solid tumours.

• Pipeline expansion expected to accelerate with established clinical and research infrastructure.